Drug intelligence / Profile preview

DWC202212

Development stage: Unknown
Modality: Small Molecules

Overview

DWC202212 is an investigational drug currently under clinical evaluation for its pharmacokinetic and pharmacodynamic properties, as well as its safety and tolerability in healthy subjects. It has been studied in combination with another investigational drug, DWC202211, to assess potential drug-drug interactions. The specific mechanism of action, primary indication, and therapeutic class are not publicly disclosed in available sources[1][2][6]. There is also a cannabis strain named "DWC 202212" (Delta-9-tetrahydrocannabinol dominant), but this appears unrelated to the pharmaceutical agent referenced here[4].

Beyond the preview

Go deeper on DWC202212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202212.

Explore the full profile